Six weeks on from the initial shock of the EU referendum result, the dust has begun to settle in Britain and industries across the four countries are starting to assess the situation they now face.
For those companies, individuals and bodies involved in clinical trials it’s likely to be a tricky break-up, for when it comes to clinical research, the UK and EU are deeply coupled. That’s clear from the pre-referendum voices of senior figures; GlaxoSmithKline CEO Andrew Witty for example: ‘Over the last 15 or 20 years, Europe has gone from 27 fragmented, independent, not-talking-to-each-other regulatory authorities in the healthcare space to one. That's a big deal.’ That’s clear also from the statistics; the UK has the second highest number of ongoing global clinical trials among EU countries, and in 2015 provided the most senior advisors to the European Medicines Agency (EMA).
However, over the last month and a half there has been an acceptance of the referendum result and many of the industry’s leading figures are already looking towards what the best moves are now. As Kieran Doran, Senior Healthcare Ethics Lecturer at University College Cork, rather theatrically puts it: ‘There are two schools of thought; either this is the end of the world as we know it, or this is a great opening that will present many exciting opportunities.’
In this report, leading industry figures assess the situation and suggest the best way forwards with regulations, movement of staff and new international partnerships.
Join the debate with over 120 influential industry speakers and 1000 attendees at Partnerships in Clinical Trials Europe in Vienna on 16-17 November 2016. Find out more here.